Basal-like breast cancers (BLBC) are aggressive breast cancers that respond poorly 27 to targeted therapies and chemotherapies. In order to define therapeutically 28 targetable subsets of BLBC we examined two markers: cyclin E1 and BRCA1 loss. 29 In high grade serous ovarian cancer (HGSOC) these markers are mutually exclusive, 30 and define therapeutic subsets. We tested the same hypothesis for BLBC. 31
INTRODUCTION 49
Breast cancer with BRCA1 mutation most often manifests as basal like breast cancer 50 (BLBC) (1), which presents difficulties for treatment as these cancers present at an 51 earlier age, at a high grade and with greater tumor burden. There are currently no 52 targeted therapies routinely used to treat BLBC (2). 53 BRCA1 is a central component of the homologous recombination DNA repair 54 pathway, and its loss results in compromised DNA damage repair (3). Alterations to 55 BRCA1 are important founder mutations for breast cancer (4), and notably, more 56 than 70% of BRCA1 mutation carriers develop early-onset BLBC based on gene 57 expression profiling (5). BRCA1 mutation directly drives the basal phenotype, and 58 mice with p53 and BRCA1 deletion develop mammary tumors with basal-like 59 characteristics (6) while intact BRCA1 represses the transcription of basal 60 cytokeratins (7) . 61
A previous report identified that BLBCs from patients with germline BRCA1 mutation 62 was associated with high cyclin E1 protein expression (8). Cyclin E1 is a cell cycle 63 regulatory protein whose gain can promote both increased proliferation and genomic 64 9 plate and treated with CYC065 (Cyclacel) or CVT313 (Thermofisher) at the 173 calculated IC 5 , IC 20 or IC 50 dose for 5 days, or treated with 10, 20 or 50nM CDK2 174 siRNA or CDK9 siRNA, or 50nM non targeting siRNA for 72 hours. Slides were 175 imaged with a fluorescence microscope (Leica DM5500) and analysed with ImageJ 176
OpenComet software (v1.3.1, (27)). 177
TCGA datasets 178
Breast cancer datasets were downloaded via cBioPortal (8) and the BLBC subset 179 identified from PAM50 definitions from TCGA 2015 (28). Biosystems) and slides were counterstained with haematoxylin. Slides were imaged 203 using a slide scanner (AperioCS2, Leica Biosystems), and data were analysed using 204 QuPath (31) as described (32) . 205
Statistical Analysis 206
Statistical analysis was performed using Prism Software TM version 7 as indicated for 207 each dataset. Data presented as box and whisker plots includes error bars of 208 minimum to maximum, with mean values indicated. Data are presented as column 209 graphs with mean +/-SEM. All experiments were performed in triplicate, except as 210 indicated. 211 11 RESULTS 212 BRCA1 inactivation associates with high cyclin E1 expression in breast 213 cancer. 214 We examined the KConFab cohort, which is enriched for familial cancer mutations, 215 for co-occurrence of germline BRCA1 mutation and high cyclin E1 expression. First, 216
we examined cyclin E1 expression by IHC ( Figure 1A ). High cyclin E1 expression 217 was defined as an H score cut-off of ≥ 45 based on the overall distribution of cyclin 218 E1 expression (Supplementary Figure S3A ), and previous reports (9,33). This cut-219 off was also associated with patient outcomes (minimal p value, Supplementary 220 Table 1 ). Overall, germline BRCA1 mutated cancers had significantly higher cyclin 221 E1 protein than the BRCA1 wildtype cases, and tumors with other breast cancer 222 associated germline mutations (BRCA2, PALB2, or CHK2) ( Figure 1B Notably, eight of the germline BRCA1 wildtype tumors had high cyclin E1. We 227 hypothesized that these may be BRCA1 methylated since our cohort was selected 228 for familial breast cancers where BRCA1 methylation is not infrequent (34). 229
Consequently, we examined the relationship between BRCA1 methylation and cyclin 230 E1 protein expression by interrogating the breast cancer dataset of the TCGA. 241 231 cases had available data for BRCA1 methylation and cyclin E1 protein expression. 232
Using a cut-off of 0.2 for methylation (35), we found that BRCA1 methylation had a 233 significant positive correlation with cyclin E1 protein expression (r=0.647, P=0.0082) 234 ( Figure 1C ). 235
Next we examined the association between cyclin E1 expression and overall survival 236 in germline BRCA1 mutated breast cancers in our cohort. High cyclin E1 expression 237 was associated with a significantly reduced overall survival of patients with BRCA1 238 mutation (233.4 vs 426.3 months, P=0.042, HR 0.34, CI 0.130-0.895) ( Figure 1D ). 239 CCNE1 amplification is not the primary driver of high expression of cyclin E1 240 in BRCA1 mutated cancers. 241
The CCNE1 gene, located on chromosome 19q12, is a frequent site of amplification 242 in cancer. We assessed CCNE1 amplification by ISH analysis of tissue sections with 243 19q12 and INSR probes to determine the 19q12/INSR ratio. Representative images 244 of 19q12 non-amplified and 19q12 amplified tumors are shown in Figure 1E . 13.5% 245 (30/222) of tumors in the entire cohort was found to be 19q12 (CCNE1) amplified. 246
The correlation between cyclin E1 protein and CCNE1 gene amplification was poor 247 (r=0.198, P=0.0031, Figure 1F ). 248
Next we assessed whether CCNE1 amplification and BRCA1 mutation co-occurred. 249
In contrast to HGSOC (12), 21/101 (20.8%) of BRCA1 mutant cases had concurrent 250 19q12 (CCNE1) amplification. This was higher than BRCA1 wildtype cases, where 251 only 6.6% had 19q12 (CCNE1) amplification ( Figure 1G ). Since 19q12 (CCNE1) 252 amplification is associated with poor survival in other cancer types we examined its 253 relationship with overall survival in BRCA1 mutated breast cancer. Unlike high 254 expression of cyclin E1, which is predictive of poor survival, 19q12 (CCNE1) 255 amplification had no prognostic value for overall survival in BRCA1 mutated breast 256 cancer ( Figure 1H ). 257
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The cyclin E1 degradation machinery is disrupted in BRCA1 mutated breast 258
cancers. 259
Since 19q12 status was only poorly predictive of high cyclin E1 expression, we thus 260 investigated other mechanisms that lead to high cyclin E1 expression. One 261 possibility was disruption of the proteasome mediated degradation of cyclin E1, 262 which occurs frequently in cancer (36). Normal cyclin E1 turnover depends upon 263 phosphorylation within two phospho-degrons on the cyclin E1 protein, of which T62 264 and T380 are crucial phosphorylation sites. The phosphorylated protein is 265 recognized by the FBXW7 module of the SCF FBXW7 complex, and ubiquitinated for 266 degradation (13). The deubiquitinase USP28 can remove ubiquitin from cyclin E1 267 and antagonise FBWX7-mediated degradation (14) (Figure 2A ). Disruption of this 268 process, ie loss of cyclin E1 phosphorylation, loss of FBXW7 or gain in USP28, 269 would be expected to increase cyclin E1 stabilization and accumulation. 270
We assessed the cyclin E1 degradation machinery by IHC in our familial breast 271 cancer cohort. We first assessed cyclin E1 T62 phosphorylation in 195 cases 272 (representative images in Figure 2B ). We observed only a moderate positive 273 correlation between cyclin E1 T62 phosphorylation and cyclin E1 expression 274 (r=0.212, p=0.003, Spearman), indicating that a proportion of cancers had very low 275 cyclin E1 T62 phosphorylation ( Figure 2C ). Consequently, we assessed the ratio of 276 cyclin E1 phosphorylation to its absolute expression to determine if phosphorylation 277 was specifically dysregulated in certain subsets of patients. We found that the 278 BRCA1 and BRCA2 mutant subsets exhibited a significantly lower T62/cyclin E1 279 ratio ( Figure 2D ), indicative of a loss of cyclin E1 phosphorylation in the absence of 280 functional BRCA1 or BRCA2. 281
14
There was no correlation between cyclin E1 and FBXW7 found in our cohort ( Figure  282 2E, F). However, BRCA1 mutated cancers had higher expression compared to the 283 BRCA2 mutant subset ( Figure 2G ). In contrast, USP28 expression was moderately 284 correlated with cyclin E1 expression (r=0.420, p<0.0001, Spearman) ( Figure 2H , I). 285 USP28 protein expression was significantly higher in the BRCA1 mutated subset 286 ( Figure 2J ). 287
In summary, BRCA1 mutated breast cancers were characterised by reduced cyclin 288 E1-T62 phosphorylation and elevated USP28 expression. Overall, these data 289 implicate increased cyclin E1 protein stability, rather than gene amplification, as the 290 cause for high cyclin E1 levels observed in BRCA1 mutated breast cancer. 291
BRCA1 loss leads to cell cycle stabilization of cyclin E1. 292
Since the cyclin E1 degradation machinery was deregulated in BRCA1 mutant 293 cancers across our cohort, we investigated whether cyclin E1 turnover is 294 dysregulated in cell lines with mutant BRCA1 or BRCA1 loss. The BLBC cell line 295 HCC1937 has a homozygous BRCA1 5382C* mutation and the triple negative breast 296 cancer (TNBC) cell line MDA-MB-436 has a BRCA1 homozygous deletion. We 297 compared these to 4 cell lines with wildtype BRCA1: BT-20 and MDA-MB-468 (BLBC 298 cell lines), MDA-MB-231 (TNBC), and SkBr3 (HER2 amplified). Cells were analysed 299 for the expression of cyclin E1 during the cell cycle using flow cytometry. BT-20, 300 MDA-MB-468, SkBr3 and MDA-MB-231 cells showed a typical downregulation of 301 cyclin E1 during S phase ( Figure 3A ), which we quantitated by comparing the 302 expression of cyclin E1 during the second half of S phase versus the first half of S 303 phase ( Figure 3B ). The BRCA1 defective cell lines showed significantly diminished 304 down-regulation of cyclin E1 during S phase: in HCC1937 cells the cyclin E1 levels 305 15 did not decrease in S phase, but instead marginally increased. There was a small 306 decrease in the absolute expression of cyclin E1 during S phase in MDA-MB-436 307 cells ( Figure 3A /B). 308
We next investigated whether knockdown of BRCA1 was able to recapitulate the cell 309 cycle stabilization of cyclin E1. First, we treated BRCA1 wildtype T-47D cells, with 310 two different BRCA1 siRNAs, siRNA#11 and siRNA#12, and a pool of the two 311 siRNAs. Both BRCA1 siRNAs led to a reproducible increase of cyclin E1 protein 312 ( Figure 3C ). Notably, this was specific to cyclin E1, and did not affect cyclin E2 313 protein ( Figure 3C ). We then specifically assessed whether BRCA1 knockdown led 314
to changes in the cell cycle expression of cyclin E1. T-47D breast cancer cells were 315 transfected with pooled BRCA1 siRNA followed by flow cytometry analysis of cells 316 immunoprobed for cyclin E1 and co-stained with propidium iodide. BRCA1 siRNA 317 treatment led to a significant increase in and prolongation of cyclin E1 protein 318 expression during late S phase and G 2 /M of the cell cycle ( Figure 3D ). In contrast, 319 CCNE1 mRNA was not increased following BRCA1 siRNA exposure ( Figure 3E ), 320 confirming that the increase in cyclin E1 expression occurs post-transcriptionally. 321 BRCA1 dysregulation specifically alters T62 phosphorylation of cyclin E1, but 322 not USP28 expression. 323
Since cyclin E1 cell cycle expression is dysregulated with BRCA1 disruption and we 324 had observed both loss of T62 phosphorylation and gain of USP28 in our cohort, we 325 sought to confirm that BRCA1 loss alters either T62 phosphorylation or USP28 326 expression to stabilise cyclin E1. 327
We first tested whether BRCA1 knockdown stabilized cyclin E1 via upregulation of 328 USP28. siRNA-mediated knockdown of USP28 in MDA-MB-231 cells led to 329 16 decreased expression of cyclin E1 (Supplementary Figure S4A) . In contrast BRCA1 330 siRNA led only to downregulation of BRCA1 but did not change USP28 levels 331 (Supplementary Figure S4B ). Thus while USP28 is elevated in BRCA1 mutant 332 cancers, we could not detect its regulation directly downstream of BRCA1. 333
Next we examined whether there was a direct relationship between changes to 334 BRCA1 expression and cyclin E1 phosphorylation. We exposed T-47D cells to 335 BRCA1 siRNA to increase cyclin E1 expression ( Figure 4A ), and subsequently 336 immunoprecipitated the lysates with the phospho-cyclin E1 T62 and phospho-cyclin 337 E1 T380 antibodies to examine the relative abundance of phosphorylation of cyclin 338 E1 at these sites. Cyclin E1 T62 was depleted following BRCA1 siRNA, in contrast 339 cyclin E1 T380 expression was sustained ( Figure 4A ). Thus the increased 340 expression of cyclin E1 following depletion of BRCA1 protein was linked directly to 341 cyclin E1 T62 dephosphorylation. 342
We performed the converse analysis by comparing UWB1.289 ovarian cancer cells 343 (germline BRCA1 mutation within exon 11 along with deletion of the wild-type allele) 344 to UWB1.289/BRCA1 cells, which stably re-express BRCA1 (37), and found that the 345 BRCA1 restored cell line had higher cyclin E1 T62 expression ( Figure 4B ). 346
Since T62 dephosphorylation can increase cyclin E1 protein stability, we analysed 347 the effect of disrupting the phospho-degrons on cyclin E1 by mutating phospho-sites 348 to alanine to mimic the non-phosphorylated state. We performed site-directed 349 mutagenesis within the two phospho-degrons of cyclin E1 ( Figure 4C ). We created 350 an N-terminal mutant (T62A, designated N-term), a C-terminal mutant 351 (T376A/S380A, designated C-term) and a combined mutant (T62A/T376A/S380A, 352 designated Dual) and stably expressed these in MDA-MB-468 BLBC cells (Figure  353   4D ). 354
We examined the effect of each mutant on the stability of the cyclin E1 protein by 355 performing flow cytometry for the V5 tag protein during the cell cycle. We measured 356 the fold change in each of the V5 tagged proteins between early and late S phase 357 (Supplementary Figure S5 ). All three mutants were significantly more stable than the 358 wildtype "high" cyclin E1 protein ( Figure 4E ). The T62A site in the N-terminus 359 stabilizes the cyclin E1 protein, and particularly in combination with mutation of the 360 C-terminal phospho-sites of cyclin E1. 361
Next, we examined the effect of each mutant on cell proliferation. Overexpression of 362 cyclin E1 wildtype and each of the cyclin E1 mutants led to a significant increase in 363
BrdU incorporation compared to the vector control ( Figure 4F ). 364
Following this we examined whether these mutants were able to alter the survival of 365 cells when treated with paclitaxel, a taxane chemotherapy used to treat BLBC 366 clinically (38). We treated vector control, cyclin E1 wildtype, and cyclin E1 mutant 367 cells with paclitaxel, and monitored survival by colony forming assay after 3-4 weeks. 368
Only the Dual mutant cells demonstrated significantly increased colony counts 369 compared to wildtype cyclin E1 overexpression (Figure 4G/4H). 370
Overall, BRCA1 loss led to decreased cyclin E1 T62 phosphorylation, which in turn 371 can increase cyclin E1 protein stability and percentage of cells in S phase. Cyclin E1 372 T62 was also critical in combination with other cyclin E1 phosphorylation sites to 373 increase cell survival in the presence of paclitaxel. 374
Synergistic targeting of cells with high cyclin E1 and BRCA1 mutation. 375
18 Our data showing that BRCA1 loss has a direct role in sustaining elevated cyclin E1 376 protein levels during S phase, supporting the rationale of co-targeting these proteins. 377
It has been demonstrated that BRCA1 deficiency leads to susceptibility to inhibition 378 of poly (ADP-ribose) polymerase (PARP), whereas cyclin E1 activates the 379 therapeutically targetable kinase CDK2. However, CDK2 also has important roles in 380 DNA repair (39), leading to increased sensitivity of BRCA1/2 mutant cancers to 381 CDK2 inhibitors (40). We thus hypothesized that treating BRCA1 mutant cancers 382 with a combination of CDK2 and PARP inhibitors would be synergistic due to the 383 simultaneous blockade of cyclin E1 dependent proliferation and exacerbated 384 synthetic lethality from PARP inhibitors due to the additional DNA damage resulting 385 from CDK2 inhibition. 386
First, we tested whether CDK2 inhibition induces DNA damage, by treating BRCA1 387 mutant HCC1937 cells with two CDK2 inhibitors, CYC065, and CVT313. After 388 establishing a dose response curve for CYC065 and CVT313 (Supplementary Figure  389 S6A and S6B), we identified induction of DNA damage using the alkaline Comet 390 assay, which detects both double strand and single strand DNA breaks ( Figure  391 5A/B). CYC065 targets CDK2, CDK5 and CDK9, but with the highest specificity to 392 CDK2. CDK5 has negligible expression in HCC1937 cells (41). We subsequently 393 confirmed that DNA damage was occurring via CDK2 action by performing comet 394 assays after treatment with CDK2 and CDK9 siRNA treatment. CDK2 siRNA 395 treatment led to an increase in tail moment detection after 72 hours of exposure at all 396 doses ( Figure 5C ). In contrast, there was no effect on DNA damage following CDK9 397 siRNA exposure ( Figure 5D ). 398 19 Next, we examined the effect of combining CDK2 inhibition with PARP inhibition. We 399 treated a BRCA1 wildtype (BT20) and BRCA1 mutant cell line (HCC1937) with 400 CYC065 and rucaparib (a PARP inhibitor). After first establishing dose response 401 curves (Supplementary data S6A/S6C), we exposed the cells to IC 50 doses of 402 CYC065 and rucaparib. The combination was significantly more effective than either 403 drug used as a single agent in the BRCA1 mutant and wildtype cell lines ( Figure 5E -404 F). There was a significant synergy demonstrated with BLISS analysis between the 405 two drugs at intersecting dose curves of CYC065 and rucaparib ( Figure 5G -H). This 406 occurred over a greater dose range in the BRCA1 mutant compared to the wildtype 407 cells, where the effect was predominantly additive. 408
Combination olaparib and CYC065 treatment leads to tumor regression in vivo. 409
We tested in vivo efficacy of the combination therapy in two PDXs of BLBC origin 410 with pathogenic BRCA1 alterations: BRCA1 R1443* mutation and truncating BRCA1 411 2080delA mutation. Following tumor implantation and expansion, each model was 412 treated with daily gavage of 50mg/kg olaparib (a PARP inhibitor) and 25mg/kg 413 CYC065 (sub-optimal doses selected for combination testing) ( Figure 6A ). In the 414 BRCA1 R1443* mutant PDX, single agent olaparib led to reduced tumor burden and 415 increased overall survival ( Figure 6B The BRCA1 2080delA model has high expression of cyclin E1, probably driven in 420 part by CCNE1 copy number gain (1.31x from exome sequencing). In this model we 421
found that both single agent olaparib and CYC065 were effective, leading to a 422 20 significant reduction in tumor volume. However, by the 60 day endpoint of the 423 experiment, several of the tumors treated with either olaparib or CYC065 had begun 424 to grow in the presence of therapy. In contrast, the combination therapy was highly 425 effective and resulted in tumor regression at the experimental endpoint ( Figure 6E , 426 F). 427
Next, we compared the effect of combination therapy to olaparib alone across the 428 two models. Olaparib therapy resulted in smaller tumors compared to controls, but 429 they were significantly larger than the starting volume (1.85x larger, P <0.013). In 430 contrast, treatment with the combination therapy led to the reduction in size of all but 431 one tumor across the two cohorts (0.51x smaller, p<0.0005; Figure 6G ). Finally, 432 since CYC065 acts via CDK2 and CDK9 inhibition, we examined the specific 433 induction of DNA damage to determine if there was evidence for inhibition of CDK2 434 in the combination treated tumors. Tumors at endpoint for vehicle showed diffuse 435 H2AX staining across the entire tumor, whereas combination treated tumors showed 436 intense H2AX foci and entire cells positive for H2AX ( Figure 6H) , with significantly 437 more intense staining in the combination treated tumors ( Figure 6I ). We also 438 We here find that BRCA1 loss reduces the turnover of cyclin E1 thereby increasing 453 proliferation and survival, providing a new therapeutic opportunity to enhance the 454 synthetic lethality of PARP inhibitors by co-targeting the cyclin E1/CDK2 axis. We 455 have used CYC065, a CDK2/CDK5/CDK9 inhibitor which has successfully 456 completed a First-in-Human Phase I clinical trial, and is continuing clinical 457 development in both solid tumors and haematological malignancies. Our studies 458 identify that CDK2 inhibitors work specifically through CDK2 to induce DNA damage 459 in vitro. We demonstrate high efficacy of combination CYC065 and olaparib in vivo 460 to induce tumor regression. Olaparib as a single agent was effective in our PDX 461 models, but several individual tumors were shown to escape therapy, and overall 462 tumor burden was increased by the experimental endpoints. We show no tumors 463 escaped inhibition with combination treatment, and almost all tumors regressed. We 464 note that the in vivo models may also have benefited from the additional inhibition of 465 CDK9 via CYC065, although with the conditions used we do not observe the 466 22 downregulation of Mcl-1 which is normally associated with CDK9 inhibition (44) 467 ( Figure 6J ). Pan-CDK inhibitors that target CDK1 or CDK12 have been 468 demonstrated in pre-clinical TNBC models to result in HR deficiency and induce 469 synthetic lethality in combination with PARP inhibitors (29). This has led to the pan-470 CDK inhibitor dinaciclib being trialed clinically in combination with the PARP inhibitor 471 veliparib in a patient cohort with TNBC (Clinical Trials Gov reference NCT01434316). 472
Our data indicates that these patients may similarly derived benefit from synthetic 473 lethality between CDK2 inhibition and PARP inhibition. 474
We found that cyclin E1 is stabilized in BRCA1 mutated breast tumors via reduced 475 phosphorylation on cyclin E1 Threonine 62, and high cyclin E1 is associated with 476 decreased overall survival for patients with BRCA1 mutation. Cyclin E1 T62 477 phosphorylation was originally believed to be of lesser importance in the turnover of 478 cyclin E1, but our work here, and that of others (45), shows that it can have 479 potentially strong effects in tumorigenesis. We find that T62A mutation is sufficient to 480 increase cyclin E1 stability and BrdU incorporation, and that T62A mutation 481 contributes to cell survival in combination with mutation of the other major phospho-482 sites of the protein. Mutation of cyclin E1 T74A and cyclin E1 T393A (equivalent to 483 human cyclin E1 T62 and T395) in a mouse model led to much higher cyclin E1 484 levels in hematopoietic and epithelial cells compared to T393A mutation alone, as 485 well as hematopoietic neoplasia (45). Delayed mammary gland involution after 486 pregnancy was also observed exclusively in the presence of the T74A mutation (45), 487 highlighting its likely importance for breast tumorigenesis. 488
The kinase responsible for T62 phosphorylation has not been identified, though it is 489 hypothesized to be a CDK2 auto-phosphorylation site based on a loose consensus 490 23 sequence for CDK2 around the T62 site, and the timing of T62 phosphorylation early 491 in G 1 phase soon after partnering with CDK2 (46). Consequently, increased T62 492 auto-phosphorylation may be the result of a direct physical interaction between 493 BRCA1 and cyclin E1/CDK2 (47) or through downstream effectors of BRCA1 action. 494
We observed that BRCA1 mutation-mediated stabilization only occurred for the 495 cyclin E1 protein, but not the closely related ortholog cyclin E2 ( Figure 3C ). This is 496 despite the phospho-T62 site being conserved between the two proteins (48). 497
However, unique to cyclin E1 is an upstream GSK3-β consensus site at S58 which is 498 hypothesized to require T62 phosphorylation in order to be phosphorylated (49). 499
In summary, we have found that CDK2 inhibition may sensitize BRCA1 mutant 500 breast cancer cells to PARP inhibitors. BRCA1 mutation most commonly associates 501 with the aggressive BLBC subtype, and thus the presence of BRCA1 mutation in 502 concert with the BLBC phenotype would suggest combination CDK2 and PARP 503 inhibition as an effective therapeutic strategy. As low levels of BRCA1 and BRCA1 504 methylation are also very common to BLBC (50), and our data demonstrates 505 elevated cyclin E1 in the BRCA1 methylated BLBC, a rational ongoing area of 506 investigation is CDK2 inhibition to sensitize BRCA1 methylated or deficient cancers 507 to PARP inhibitors. 508 
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